because you consistently make a point to bring this up, but (unless ive missed it) never explain why extended dosing is important.
why is extended dosing significant?
Good point.....you've become a"broken record"on this board but I have to admit you bring up valid points. They are paying 5.2 billion for a drug still under review.
I really believe the potential of aldox is down played. Dox has many applications and I continuously hear how aldox is "superior" to dox
If approved...aldox. well be a blockbuster drug.
cpxx and cytr are two different companies.....Why must people continue to compare the two? If cpxxx goes up, does not mean cytr will go up. and vice versa
Mark this message.....When Donald Trump wins the Presidency, real estate will be the place to put your money for the next 4 years and beyond. "The Donald" is a real estate guy and will get this sector jumpstarted.
What works for me is to sell some but not all ,that way if it pops again you still have shares on the table to enjoy the ride.
If aldox is proven to be more efficient and less toxic...its a no brainer.... whatever steps dox has taken aldox will do the same. Simple math folks.
Acute lymphoblastic leukemia (ALL)
• Acute myeloblastic leukemia (AML)
• Bone sarcoma
• Breast cancer
• Endometrial cancer
• Gastric cancer
• Head and neck cancer
• Hodgkin lymphoma
• Non-Hodgkin lymphoma
• Liver cancer
• Kidney cancer
• Multiple myeloma
• Ovarian cancer
• Small Cell Lung cancer
• Soft tissue sarcoma
• Thyroid cancer
• Transitional cell bladder cancer
• Uterine sarcoma
• Wilms’ tumor
• Waldenström macroglobulinemia
I think hold or watch for a catalyst is in order here....JMP made the right call here. Ive been investing in the company for a long time. Its not an industry leader and the stock price has only jumped twice in the past 6 or 7 years. Once when the government gave a tax break to new home buyers and the other from the recent cash call purchace. Each time the pps fell substantially from the high. So I've learned twice that unless Uncle Sam gives a stimulus to this sector or the company makes a move that will clearly signal growth, market perform/hold is the right call. Right now I'm completely out of Impac for the reason above. Each major move in 7 years have all been telegraphed. Outside a buyout I think this is a good rule of thumb for this stock. GLTA
To add to my "medical game changer"comment....this is why I wouldn't be surprised to see multiple bids to buy cytrx.
Cardiotoxicity is the occurrence of heart electrophysiology dysfunction or muscle damage. The heart becomes weaker and is not as efficient in pumping and therefore circulating blood.